Literature DB >> 19203802

Duration and extent of dysphagia following pediatric airway reconstruction.

Claire Kane Miller1, Jessica Linck, Jay Paul Willging.   

Abstract

OBJECTIVE: Patients who undergo open airway reconstruction procedures are likely to experience some degree of post-operative dysphagia. This retrospective review describes the duration of post-operative dysphagia and the use of compensatory strategies in a group of 30 pediatric patients.
METHODS: A retrospective chart review of pediatric patients referred for post-operative swallowing assessment following airway reconstruction during a six-month period was completed. Age, sex, surgical procedure, stent type, co-morbid factors, duration of dysphagia, and use of compensatory dietary modifications and swallowing strategies was summarized and compared.
RESULTS: Dysphagia was generally of short duration (1-5 days) in patients undergoing single stage procedures with anterior or anterior/posterior grafts. Duration of swallowing difficulty was increased in patients undergoing posterior grafts in combination with T tubes (10-14 days). The longest duration of difficulty (>2 weeks) occurred in patients who had anterior and posterior grafting with T tubes, combined with additional procedures such as vocal fold lateralization, epiglottic petiole repositioning, and/or arytenoidectomy. There was a greater likelihood of oral feeding difficulty post-operatively in patients presenting with pre-operative feeding issues such as oral aversion or specific texture refusal, and the pre-morbid need for supplemental tube feeding to supplement oral intake. Compensatory swallowing strategies were effective in decreasing aspiration associated with swallowing in oral feeders post-operatively, and in facilitating return to baseline swallowing skills.
CONCLUSIONS: The duration of dysphagia overall was increased in patients undergoing anterior/posterior grafts in conjunction with in-dwelling T tubes, especially when combined with additional procedures. Compensatory strategies to assist with swallowing were found to be effective in the post-operative phase and included the use of a modified supraglottic swallowing sequence to assist with compensatory airway closure during swallowing in conjunction with diet modifications. Post-operative feeding difficulty occurred in patients with pre-existing feeding issues such as oral aversion and/or texture resistance regardless of reconstructive surgical procedure type.

Entities:  

Mesh:

Year:  2009        PMID: 19203802     DOI: 10.1016/j.ijporl.2008.12.024

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  3 in total

1.  Disease homogeneity and treatment heterogeneity in idiopathic subglottic stenosis.

Authors:  Alexander Gelbard; Donald T Donovan; Julina Ongkasuwan; S A R Nouraei; Guri Sandhu; Michael S Benninger; Paul C Bryson; Robert R Lorenz; William S Tierney; Alexander T Hillel; Shekhar K Gadkaree; David G Lott; Eric S Edell; Dale C Ekbom; Jan L Kasperbauer; Fabien Maldonado; Joshua S Schindler; Marshall E Smith; James J Daniero; C Gaelyn Garrett; James L Netterville; Otis B Rickman; Robert J Sinard; Christopher T Wootten; David O Francis
Journal:  Laryngoscope       Date:  2015-11-04       Impact factor: 3.325

2.  Prevalence and incidence of idiopathic subglottic stenosis in southern and central Alberta: a retrospective cohort study.

Authors:  Ryan K Chan; Beau Ahrens; Paul MacEachern; J Douglas Bosch; Derrick R Randall
Journal:  J Otolaryngol Head Neck Surg       Date:  2021-11-12

3.  Treatment options in idiopathic subglottic stenosis: protocol for a prospective international multicentre pragmatic trial.

Authors:  Alexander Gelbard; Yu Shyr; Lynne Berry; Alexander T Hillel; Dale C Ekbom; Eric S Edell; Jan L Kasperbauer; David G Lott; Donald T Donovan; C Gaelyn Garrett; Guri Sandhu; James J Daniero; James L Netterville; Josh S Schindler; Marshall E Smith; Paul C Bryson; Robert R Lorenz; David O Francis
Journal:  BMJ Open       Date:  2018-04-10       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.